Sabine Mai
Founder bei TELO GENOMICS CORP.
Vermögen: 233 266 $ am 31.03.2024
Profil
Sabine Mai is the founder of Telo Genomics Corp.
which was founded in 2011.
She holds the title of Director at Telo Genomics Corp.
Dr. Mai's current jobs include being a Director at The Genomic Centre For Cancer Research & Diagnosis and a Professor at the University of Manitoba.
Dr. Mai's former job was being a Director at 3D Signatures, Inc.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
TELO GENOMICS CORP.
3,95% | 08.12.2023 | 2 810 433 ( 3,95% ) | 233 266 $ | 31.03.2024 |
Aktive Positionen von Sabine Mai
| Unternehmen | Position | Beginn |
|---|---|---|
| TELO GENOMICS CORP. | Founder | 25.05.2011 |
| University of Manitoba | Corporate Officer/Principal | - |
| The Genomic Centre For Cancer Research & Diagnosis | Director/Board Member | - |
Ehemalige bekannte Positionen von Sabine Mai
| Unternehmen | Position | Ende |
|---|---|---|
3D Signatures, Inc. /Old/
 3D Signatures, Inc. /Old/ Medical/Nursing ServicesHealth Services 3D Signatures, Inc. develops diagnostic and prognostic products. It provides diagnostic and prognostic tools for cancer and Alzheimer's disease. 3D Signatures is in the process of developing 3D Telo-PC for prostate cancer and 3D Telo-RS for Hodgkin’s Lymphoma. The company is headquartered in Winnipeg, Canada. | Director/Board Member | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| TELO GENOMICS CORP. | Health Services |
| Private Unternehmen | 2 |
|---|---|
3D Signatures, Inc. /Old/
3D Signatures, Inc. /Old/ Medical/Nursing ServicesHealth Services 3D Signatures, Inc. develops diagnostic and prognostic products. It provides diagnostic and prognostic tools for cancer and Alzheimer's disease. 3D Signatures is in the process of developing 3D Telo-PC for prostate cancer and 3D Telo-RS for Hodgkin’s Lymphoma. The company is headquartered in Winnipeg, Canada. | Health Services |
| The Genomic Centre For Cancer Research & Diagnosis |
